113 related articles for article (PubMed ID: 26062755)
41. Double-edged sword: a p53 regulator mediates both harmful and beneficial effects in experimental acute kidney injury.
McNicholas BA; Griffin MD
Kidney Int; 2012 Jun; 81(12):1161-4. PubMed ID: 22648356
[TBL] [Abstract][Full Text] [Related]
42. The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.
Fierabracci A; Pellegrino M
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27897991
[TBL] [Abstract][Full Text] [Related]
43. Tumor suppression by p53 without accelerated aging: just enough of a good thing?
Mendrysa SM; Perry ME
Cell Cycle; 2006 Apr; 5(7):714-7. PubMed ID: 16582632
[TBL] [Abstract][Full Text] [Related]
44. [MDM2 promotes cell death by interacting with mitochondrial bioenergetics].
Gaillard B; Juarez-Krieguer C; Golinelli-Cohen MP
Med Sci (Paris); 2021 Apr; 37(4):397-399. PubMed ID: 33908859
[TBL] [Abstract][Full Text] [Related]
45. Hsp90 inhibition protects brain endothelial cells against LPS-induced injury.
Uddin MA; Akhter MS; Kubra KT; Barabutis N
Biofactors; 2022 Jul; 48(4):926-933. PubMed ID: 35266593
[TBL] [Abstract][Full Text] [Related]
46. The role of interleukin-17 in tumor development and progression.
Zhao J; Chen X; Herjan T; Li X
J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31727782
[TBL] [Abstract][Full Text] [Related]
47. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.
Schetter AJ; Heegaard NH; Harris CC
Carcinogenesis; 2010 Jan; 31(1):37-49. PubMed ID: 19955394
[TBL] [Abstract][Full Text] [Related]
48. A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.
Kazantseva M; Mehta S; Eiholzer RA; Hung N; Wiles A; Slatter TL; Braithwaite AW
Mamm Genome; 2018 Dec; 29(11-12):831-842. PubMed ID: 29992419
[TBL] [Abstract][Full Text] [Related]
49. Immunometabolic function of the transcription cofactor VGLL3 provides an evolutionary rationale for sexual dimorphism in autoimmunity.
Pagenkopf A; Liang Y
FEBS Lett; 2020 Oct; 594(20):3371-3383. PubMed ID: 32803756
[TBL] [Abstract][Full Text] [Related]
50. Paracrine control of tissue regeneration and cell proliferation by Caspase-3.
Boland K; Flanagan L; Prehn JH
Cell Death Dis; 2013 Jul; 4(7):e725. PubMed ID: 23846227
[TBL] [Abstract][Full Text] [Related]
51. Origin and physiological roles of inflammation.
Medzhitov R
Nature; 2008 Jul; 454(7203):428-35. PubMed ID: 18650913
[TBL] [Abstract][Full Text] [Related]
52. Inflammatory mediators: Parallels between cancer biology and stem cell therapy.
Patel SA; Heinrich AC; Reddy BY; Rameshwar P
J Inflamm Res; 2009 Jan; 2():13-19. PubMed ID: 20428325
[TBL] [Abstract][Full Text] [Related]
53. Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization.
Linkermann A; Kulms D
Cell Death Dis; 2019 Dec; 10(12):910. PubMed ID: 31801943
[No Abstract] [Full Text] [Related]
54. Extracellular and intracellular functions of coiled-coil domain containing 3.
Omari S; Lee H; Wang J; Zeng SX; Lu H
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37263799
[TBL] [Abstract][Full Text] [Related]
55. Letter to the Editor: The Versatility of Tumor Suppressor Proteins and its Therapeutic Potential.
Radulescu RT
Protein Pept Lett; 2017; 24(8):684. PubMed ID: 28875829
[No Abstract] [Full Text] [Related]
56. Cell and Molecular Mechanics in Health and Disease.
Kawauchi K; Fujita H; Miyoshi D; Yim EK; Hirata H
Biomed Res Int; 2017; 2017():2860241. PubMed ID: 28321404
[No Abstract] [Full Text] [Related]
57. Cell death in human health and disease.
Xu J; Wang D; Ma W
Biomed Res Int; 2014; 2014():243017. PubMed ID: 25136567
[No Abstract] [Full Text] [Related]
58. Regulation of the p53 response and its relationship to cancer.
Meek DW
Biochem J; 2015 Aug; 469(3):325-46. PubMed ID: 26205489
[TBL] [Abstract][Full Text] [Related]
59. Transcription factors that interact with p53 and Mdm2.
Inoue K; Fry EA; Frazier DP
Int J Cancer; 2016 Apr; 138(7):1577-85. PubMed ID: 26132471
[TBL] [Abstract][Full Text] [Related]
60. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment.
Urso L; Calabrese F; Favaretto A; Conte P; Pasello G
Crit Rev Oncol Hematol; 2016 Jan; 97():220-30. PubMed ID: 26358421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
